Back to today’s briefing

Story perspectives

Aspirin Cuts Colorectal Cancer Recurrence Risk by 55%

10/5/2025

46 7

Summary

Story summary

Daily low-dose aspirin reduced colorectal cancer recurrence risk by 55% in patients with genetic mutations.
The Karolinska Institutet-led trial enrolled more than 3,500 patients across Sweden, Norway, Denmark, and Finland.
The randomized study, published in The New England Journal of Medicine, confirms aspirin's protective effect.
Aspirin may slow tumor growth by reducing inflammation and inhibiting platelet function.

1 of 1

Story summary

Daily low-dose aspirin reduced colorectal cancer recurrence risk by 55% in patients with genetic mutations.
The Karolinska Institutet-led trial enrolled more than 3,500 patients across Sweden, Norway, Denmark, and Finland.
The randomized study, published in The New England Journal of Medicine, confirms aspirin's protective effect.
Aspirin may slow tumor growth by reducing inflammation and inhibiting platelet function.